C-Based Single-Domain Antibody for RSV F-Protein Neutralization

Solution Overview

Problem

There is an urgent need for effective vaccines and therapeutic drugs to treat respiratory syncytial virus (RSV) infections, as current treatments like Ribavirin and Palivizumab have significant side effects or limited efficacy.

Innovation Solution

Development of a C-based single domain antibody, BBT-VC001-1, derived from the CH2 domain of human IgG1, specifically targeting the RSV F protein, which is expressed and purified to neutralize RSV, with variants showing similar activity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If Ribavirin is used for antiviral treatment, then antiviral effect is achieved, but side effects are high and specificity is low

Engineering Contradiction:

Improveantiviral effectVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent extracts the essential protective function from complex full-length monoclonal antibodies by isolating and utilizing only the C-domain (constant domain 2, CH2), which contains the key neutralizing activity against RSV. This extracted C-domain antibody maintains antiviral efficacy while eliminating the problematic portions of the full antibody molecule that contribute to side effects and complexity.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The C-domain antibody is designed as a simplified, smaller molecular weight antibody fragment that can be produced more economically than full-length monoclonal antibodies. The reduced size and simplified structure enable lower production costs and easier manufacturing, making it a more accessible therapeutic option.

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

2Reliability

If Palivizumab monoclonal antibody is used for prevention, then preventive effect is achieved, but cost is expensive and neutralizing activity is weak

Engineering Contradiction:

Improvepreventive effectVSAvoidproduction cost

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The patent extracts the essential protective function from complex full-length monoclonal antibodies by isolating and utilizing only the C-domain (constant domain 2, CH2), which contains the key neutralizing activity against RSV. This extracted C-domain antibody maintains antiviral efficacy while eliminating the problematic portions of the full antibody molecule that contribute to side effects and complexity.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The C-domain antibody is designed as a simplified, smaller molecular weight antibody fragment that can be produced more economically than full-length monoclonal antibodies. The reduced size and simplified structure enable lower production costs and easier manufacturing, making it a more accessible therapeutic option.

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

3Reliability

If full-length monoclonal antibodies are used, then neutralizing activity is achieved, but tissue penetration is limited and production cost is high

Engineering Contradiction:

Improveneutralizing activityVSAvoidmolecular weight

Core Design Contradiction:

ReliabilityVSLength of moving object

Solution Approach 1:

The patent segments the full-length monoclonal antibody into smaller functional units, specifically utilizing only the C-domain (CH2) portion. This segmentation creates a smaller molecular weight antibody fragment that retains neutralizing activity while improving tissue penetration capabilities and reducing production complexity.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent extracts the essential protective function from complex full-length monoclonal antibodies by isolating and utilizing only the C-domain (constant domain 2, CH2), which contains the key neutralizing activity against RSV. This extracted C-domain antibody maintains antiviral efficacy while eliminating the problematic portions of the full antibody molecule that contribute to side effects and complexity.

Inventive Principle:

Principle #2Taking out (Extraction)

Data Source

PatentUS12410242B2C-based single domain antibody for neutralizing respiratory syncytial virus and application thereof

Publication Date: 2025.09.09 WUHAN BANKE BIOTECHNOLOGY CO LTD

AI summary

The present disclosure relates to a C-based single domain antibody that neutralizes respiratory syncytial virus (RSV) and its application thereof. The C-based single domain antibody of the present disclosure is a neutralizing antibody against RSV F protein, can inhibit the viral entry into host cells, and can be used for the prevention, treatment and diagnosis of RSV, as well as for further studying the mechanism of RSV infection. The C-based single domain antibody has a smaller molecular weight, better tissue permeability and the ability to bind to antigenic epitope with steric hindrance effect; it can be expressed in multiple expression systems, including prokaryotic, yeast, and mammalian cells. The C-based single domain antibody has a low production cost and a short production cycle; it has a wide range of administration routes and can be administered through nasal drops, nasal spray, spray, aerosol inhalation, intramuscular injection, intravenous injection, subcutaneous injection, etc.